An energy transition venture team has moved into the Ion. Photo courtesy of The Ion

A Houston-based venture capital firm has been busy — with deploying capital, growing its team, and moving into new space.

Energy Transition Ventures has opened an office in the Ion Houston. The fund, which was announced last year, was founded by Craig Lawrence and Neal Dikeman — two former Silicon Valley venture capitalists with Texas ties. The team has a presence in Austin, as well as a satellite office in San Mateo.

"We’re excited after working remotely since we 'opened our doors' during the pandemic, to place our first office in the Ion," says Dikeman, adding that he's excited to work with the community's leadership. "I know several other investors have been looking or are in process to relocate to the Ion, but I believe we are the first venture capital fund to move in. Looking forward to the time when we are just one of long list of funds competing for startup founders’ attentions at Ion."

In addition to the new office space, ETV has also added a third investing partner. Q Song — vice president of GS Group, which was an early investor in the fund — relocated from Seoul, Korea, to Houston last summer to join the organization full time.

“Houston is a natural fit both professionally and personally," Song says. "GS Group has been partnered with Chevron in the GS Caltex refinery, one of five largest refineries in the world, for decades, and there is a huge Korean expat community here as well. For ETV, we needed a place like the Ion both suitable for hosting investors and executives when they come to town, and where startup founders feel comfortable and at home.”

The firm has made investments in four startups, and three have been announced publicly, Dikeman says. The most recent investment was in green hydrogen company Ohmium, which was founded by former SunEdison, Bloom Energy, and Plug Power executives and closed a $45 million round last month.

ETV has also invested in Dronebase, an aerial inspection company for renewables, and Resilient Power, a power electronics startup launching a next generation EV Fastcharging product.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.